BliNK Biomedical SAS is developing novel therapeutic antibodies focused on immuno-oncology. The lead programme is a monoclonal antibody against an immune checkpoint applicable for a wide range of haematological and solid tumours. To complete its proprietary pipeline, BliNK Biomedical SAS is addressing a number of novel targets from families such as GPCRs, which are not easily accessible by standard technologies.
BliNK Biomedical successfully developed antibodies against a panel of human and veterinary targets as part of past and on-going collaborations. These programs have clearly validated the platform's capabilities for challenging targets.
We are always looking to collaborate with leading academic institutions to advance our programs and are engaged in several collaborations at the moment. If you believe that your expertise could be of value to us please feel free to contact us. BliNK will be able to provide funding, but we can, however, not pay for than 5% of the total project costs to cover indirect costs.
Programs for out-licensing
BliNK Biomedical SAS has discovered high quality fully human monoclonal antibodies against several infectious disease targets to be partnered. Please contact us for more information.